Violeta Serra

Barcelona, CT 08035, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 130 publications

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Patient-derived xenograft models of primary breast cancer for preclinical evaluation of neoadjuvant therapies.

Journal: Science translational medicine

Published: March 18, 2026

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.

Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer.

Journal: NPJ breast cancer

Published: February 13, 2026

Modulation of splicing factors SF3B1 and SRSF1 by polypurine reverse Hoogsteen hairpins affects the splicing pattern of estrogen receptor α in breast cancer cells.

Modulation of splicing factors SF3B1 and SRSF1 by polypurine reverse Hoogsteen hairpins affects the splicing pattern of estrogen receptor α in breast cancer cells.

Journal: Cancer cell international

Published: January 30, 2026

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Application of a translational research platform to unveil efficacy signals and mechanisms of resistance of FGFR inhibitors in multiple FGFR-altered solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 27, 2026

Publisher Correction: Interpretable inflammation landscape of circulating immune cells.

Publisher Correction: Interpretable inflammation landscape of circulating immune cells.

Journal: Nature medicine

Published: January 26, 2026

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program.

Journal: NPJ precision oncology

Published: January 23, 2026

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Impact of BRCA2 pathogenic variants on outcomes to first-line CDK4/6 inhibitors plus endocrine therapy in HR-positive/HER2-negative metastatic breast cancer.

Journal: ESMO open

Published: December 17, 2025

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.

Journal: NPJ breast cancer

Published: July 31, 2025

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer.

Journal: Cell reports

Published: June 18, 2025

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.

Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.

Journal: NPJ precision oncology

Published: June 17, 2025

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer.

Journal: NPJ precision oncology

Published: June 05, 2025

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models.

DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models.

Journal: DNA repair

Published: February 12, 2025

Showing 1-12 of 130

Last Updated: 09/26/2026